Topiramate
Product Images NDC 70934-768

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 768 30 Master Bottle Label Approval Rev A 01 21)

Label for Topiramate Tablets USP 100 mg by Denton Pharma, Inc. DBA Northwind Pharmaceuticals. The label states 30 tablets per container, prescription only. It includes storage instructions to keep at 20°-25°C (68°-77°F) and to protect from moisture, plus a note to see package insert for dosage. The label displays the NDC: 70934-768-30 and includes lot, expiration, and manufacturer details.*

FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 01)

Chemical structure of topiramate, showing its molecular configuration with multiple ring systems and functional groups including sulfonamide and ether moieties.*

FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 02)

A Kaplan-Meier plot showing cumulative rates for time to first seizure over 500 days for two topiramate dosage groups: 50 mg/day and 400 mg/day. The solid line represents the 50 mg/day group (N=234), and the dashed line the 400 mg/day group (N=236). The graph includes a p-value of 0.0002, indicating a statistical comparison between the two groups.*

FDA Label Image

Topiramate Tablets Usp (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 03)

A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate for placebo and topiramate doses of 50 mg/day, 100 mg/day, and 200 mg/day. The chart displays results from two studies, labeled Study 11 and Study 12, with error bars indicating standard error. Significant reductions (* p <0.010, ** p <0.001) are marked for the 100 mg/day and 200 mg/day doses compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.